Drug Profile
Ligufalimab - Akeso Biopharma
Alternative Names: AK 117Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Colorectal cancer; Gastric cancer; Myelodysplastic syndromes; Oesophageal cancer; Triple negative breast cancer
- Phase I/II Acute myeloid leukaemia; Solid tumours
- Phase I Lymphoma
Most Recent Events
- 07 Feb 2024 Phase-II clinical trials in Myelodysplastic syndromes (Combination therapy, Newly diagnosed) in China, USA (IV) (NCT06196203)
- 09 Jan 2024 Akeso Biopharma plans a phase II trial for Myelodysplastic syndromes (Combination therapy, Newly-diagnosed) in January 2024 (IV) (NCT06196203)
- 25 Dec 2023 Ligufalimab is still in phase I trials for Lymphoma (Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)